CUGBP1 and p21 in Cancer Cell Resistance to Bortezomib
Author Information
Author(s): Gareau Cristina, Fournier Marie-Josée, Filion Christine, Coudert Laetitia, Martel David, Labelle Yves, Mazroui Rachid
Primary Institution: Laval University, CHUQ Research Centre/St-François d'Assise Research Centre
Hypothesis
Does CUGBP1 play a role in the stabilization of p21 mRNA and contribute to resistance against bortezomib-induced apoptosis?
Conclusion
CUGBP1-mediated p21 mRNA accumulation promotes resistance to bortezomib-induced apoptosis in cancer cells.
Supporting Evidence
- Bortezomib treatment leads to the accumulation of p21 mRNA in stress granules.
- CUGBP1 is required for the stabilization of p21 mRNA during bortezomib treatment.
- Depletion of p21 increases apoptosis in cancer cells treated with bortezomib.
- CUGBP1 depletion reduces p21 mRNA levels and sensitizes cells to bortezomib-induced apoptosis.
Takeaway
This study shows that a protein called CUGBP1 helps stabilize another protein called p21, which protects cancer cells from dying when treated with a drug called bortezomib.
Methodology
The study involved treating cancer cells with bortezomib and analyzing the effects on p21 mRNA levels and stress granule formation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website